239463-89-9

Basic information

• Product Name: 4-CHLORO-6,8-DIFLUOROQUINOLINE
• Synonyms: BUTTPARK 30\09-66;4-CHLORO-6,8-DIFLUOROQUINOLINE;Quinoline, 4-chloro-6,8-difluoro-
• CAS NO: 239463-89-9
• Molecular Formula: C9H4ClF2N
• Molecular Weight: 199.58
• Mol File: 239463-89-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 256.9°C at 760 mmHg
• Flash Point: 109.1°C
• Appearance: /
• Density: 1.455g/cm³
• Vapor Pressure: 0.0242mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-CHLORO-6,8-DIFLUOROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6,8-DIFLUOROQUINOLINE(239463-89-9)
• EPA Substance Registry System: 4-CHLORO-6,8-DIFLUOROQUINOLINE(239463-89-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 239463-89-9(Hazardous Substances Data)

Usage

General Description

4-Chloro-6,8-difluoroquinoline is a chemical compound with the molecular formula C9H4ClF2N. It is a fluorinated quinoline derivative that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 4-CHLORO-6,8-DIFLUOROQUINOLINE is known for its fluorine-substituted quinoline structure, which imparts unique chemical and biological properties. It is often utilized in the development of new drugs and agrochemicals due to its potential pharmacological and pesticidal activities. Additionally, 4-chloro-6,8-difluoroquinoline has been studied for its antimicrobial and antiparasitic properties, making it a valuable tool in medicinal chemistry research. Overall, this compound has important applications in the fields of pharmaceuticals and agrochemicals, contributing to the development of new and improved products for various industries.

InChI:InChI=1/C9H4ClF2N/c10-7-1-2-13-9-6(7)3-5(11)4-8(9)12/h1-4H

Upstream product

• 1071541-70-2 5-[(3,5-difluoro-phenylamino)-methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 372-39-4 3,5-difluoroaniline 
• 1384272-23-4 6,8-difluoroquinolin-4(1H)-one 
• 367-25-9 2,4-difluorophenylamine 
• 243448-16-0 4-hydroxy-6,8-difluoro-quinoline 

Downstream Products

• 1384272-31-4 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(5-fluoro-2-methylphenyl)urea 
• 1384272-32-5 1-(2-chloro-5-(trifluoromethyl)phenyl)-3-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)urea 
• 1384272-33-6 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(4-isopropylphenyl)urea 
• 1384272-34-7 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(3,4-dimethylphenyl)urea 
• 1384272-25-6 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(2-(trifluoromethoxy)phenyl)urea 
• 1384272-26-7 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(4-(trifluoromethoxy)phenyl)urea 
• 1384272-27-8 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(2-(trifluoromethyl)phenyl)urea 
• 1384272-28-9 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(4-(trifluoromethyl)phenyl)urea 
• 1384272-30-3 1-(3-chloro-2-fluorophenyl)-3-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)urea 

Relevant articles and documents

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

AURORA KINASE MODULATORS AND METHOD OF USE

The present invention relates to chemical compounds having a general formula I {INSERT STRUCTURE HERE} wherein A1-8, D,, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.